公开(公告)号：US12144801B2

公开(公告)日：2024-11-19

申请号：US17863902

申请日：2022-07-13

Applicant: Ovid Therapeutics Inc.

Inventor： Matthew During

IPC: A61K31/437 ,  A61K9/00 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/27 ,  A61K31/325 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/433 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/513 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/57 ,  A61K31/7048 ,  A61K45/06

Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

公开(公告)号：US12109201B2

公开(公告)日：2024-10-08

申请号：US17843028

申请日：2022-06-17

Applicant: Ovid Therapeutics, Inc.

Inventor： Matthew During

IPC: A61K31/437 ,  A61K9/00 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/27 ,  A61K31/325 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/433 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/513 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/57 ,  A61K31/7048 ,  A61K45/06

CPC classification number: A61K31/437 ,  A61K9/0019 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/27 ,  A61K31/325 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/433 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/513 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/57 ,  A61K31/7048 ,  A61K45/06 ,  A61K31/437 ,  A61K2300/00 ,  A61K31/57 ,  A61K2300/00 ,  A61K31/5517 ,  A61K2300/00 ,  A61K31/5513 ,  A61K2300/00 ,  A61K31/44 ,  A61K31/04 ,  A61K2300/00 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00 ,  A61K31/433 ,  A61K2300/00 ,  A61K31/55 ,  A61K2300/00 ,  A61K31/4015 ,  A61K2300/00 ,  A61K31/195 ,  A61K2300/00 ,  A61K31/165 ,  A61K2300/00 ,  A61K31/53 ,  A61K2300/00 ,  A61K31/444 ,  A61K2300/00 ,  A61K31/515 ,  A61K2300/00 ,  A61K31/4166 ,  A61K2300/00 ,  A61K31/4192 ,  A61K2300/00 ,  A61K31/19 ,  A61K2300/00 ,  A61K31/513 ,  A61K2300/00 ,  A61K31/36 ,  A61K2300/00 ,  A61K31/4535 ,  A61K2300/00 ,  A61K31/7048 ,  A61K2300/00 ,  A61K31/197 ,  A61K2300/00 ,  A61K31/423 ,  A61K2300/00 ,  A61K31/136 ,  A61K2300/00

Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

公开(公告)号：US20240173280A1

公开(公告)日：2024-05-30

申请号：US18428488

申请日：2024-01-31

Applicant: Ovid Therapeutics Inc.

Inventor： Matthew During

IPC: A61K31/196 ,  A61P25/08

CPC classification number: A61K31/196 ,  A61P25/08

Abstract: Methods of treating a seizure disorder with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of a seizure disorder. Methods of treating Prader-Willi syndrome with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of Prader-Willi syndrome.

公开(公告)号：US11806336B2

公开(公告)日：2023-11-07

申请号：US18296532

申请日：2023-04-06

Applicant: Ovid Therapeutics Inc.

Inventor： Matthew During

IPC: A61K31/437 ,  A61K31/57 ,  A61K31/5513 ,  A61K31/325 ,  A61K31/44 ,  A61K31/433 ,  A61K31/55 ,  A61K31/4015 ,  A61K31/195 ,  A61K31/165 ,  A61K31/53 ,  A61K31/444 ,  A61K31/515 ,  A61K31/4166 ,  A61K31/197 ,  A61K9/00 ,  A61K45/06 ,  A61K31/19 ,  A61K31/27 ,  A61K31/36 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/4535 ,  A61K31/513 ,  A61K31/5517 ,  A61K31/7048

CPC classification number: A61K31/437 ,  A61K9/0019 ,  A61K31/165 ,  A61K31/19 ,  A61K31/195 ,  A61K31/197 ,  A61K31/27 ,  A61K31/325 ,  A61K31/36 ,  A61K31/4015 ,  A61K31/4166 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/433 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4535 ,  A61K31/513 ,  A61K31/515 ,  A61K31/53 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/57 ,  A61K31/7048 ,  A61K45/06 ,  A61K31/437 ,  A61K2300/00 ,  A61K31/57 ,  A61K2300/00 ,  A61K31/5517 ,  A61K2300/00 ,  A61K31/5513 ,  A61K2300/00 ,  A61K31/44 ,  A61K2300/00 ,  A61K31/27 ,  A61K2300/00 ,  A61K31/433 ,  A61K2300/00 ,  A61K31/55 ,  A61K2300/00 ,  A61K31/4015 ,  A61K2300/00 ,  A61K31/195 ,  A61K2300/00 ,  A61K31/165 ,  A61K2300/00 ,  A61K31/53 ,  A61K2300/00 ,  A61K31/444 ,  A61K2300/00 ,  A61K31/515 ,  A61K2300/00 ,  A61K31/4166 ,  A61K2300/00 ,  A61K31/4192 ,  A61K2300/00 ,  A61K31/19 ,  A61K2300/00 ,  A61K31/513 ,  A61K2300/00 ,  A61K31/36 ,  A61K2300/00 ,  A61K31/4535 ,  A61K2300/00 ,  A61K31/7048 ,  A61K2300/00 ,  A61K31/197 ,  A61K2300/00 ,  A61K31/423 ,  A61K2300/00 ,  A61K31/136 ,  A61K2300/00

Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

公开(公告)号：US20230071127A1

公开(公告)日：2023-03-09

申请号：US17981148

申请日：2022-11-04

Applicant: Ovid Therapeutics Inc.

Inventor： Matthew DURING

IPC: A61K31/437 ,  A61P25/14 ,  A61P25/00

Abstract: Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder.

公开(公告)号：US20220323424A1

公开(公告)日：2022-10-13

申请号：US17843028

申请日：2022-06-17

Applicant: Ovid Therapeutics, Inc.

Inventor： Matthew During

IPC: A61K31/437 ,  A61K31/57 ,  A61K31/5513 ,  A61K31/325 ,  A61K31/44 ,  A61K31/433 ,  A61K31/55 ,  A61K31/4015 ,  A61K31/195 ,  A61K31/165 ,  A61K31/53 ,  A61K31/444 ,  A61K31/515 ,  A61K31/4166 ,  A61K31/197 ,  A61K9/00 ,  A61K45/06 ,  A61K31/19 ,  A61K31/27 ,  A61K31/36 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/4535 ,  A61K31/513 ,  A61K31/5517 ,  A61K31/7048

Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

公开(公告)号：US11364228B2

公开(公告)日：2022-06-21

申请号：US17126168

申请日：2020-12-18

Applicant: Ovid Therapeutics Inc.

Inventor： Matthew During

IPC: A61K31/4355 ,  A61K31/437

Abstract: Methods and pharmaceutical compositions containing gaboxadol or a pharmaceutically acceptable salt thereof for treating 1p36 deletion syndrome are provided.

公开(公告)号：US20220110917A1

公开(公告)日：2022-04-14

申请号：US17558195

申请日：2021-12-21

Applicant: Ovid Therapeutics Inc.

Inventor： Matthew DURING

IPC: A61K31/4162 ,  A61K31/573

Abstract: Use of gaboxadol, allopregnanolone, or ganaxolone, or a pharmaceutical salt of any of the foregoing, for the treatment of cervical dystonia, multiple system atrophy, myoclonus, progressive supranuclear palsy, restless legs syndrome, Wilson's disease, ataxia, chorea, or dystonia in a subject in need thereof.

公开(公告)号：US20210283075A1

公开(公告)日：2021-09-16

申请号：US17336758

申请日：2021-06-02

Applicant: Ovid Therapeutics, Inc.

Inventor： Matthew During

IPC: A61K31/145 ,  A61P25/22

Abstract: Methods and compositions for treating Attention-deficit/hyperactivity disorder are provided which include administering to a patient in need thereof captodiamine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210186938A1

公开(公告)日：2021-06-24

申请号：US17126168

申请日：2020-12-18

Applicant: Ovid Therapeutics Inc.

Inventor： Matthew DURING

IPC: A61K31/437

Abstract: Methods and pharmaceutical compositions containing gaboxadol or a pharmaceutically acceptable salt thereof for treating 1p36 deletion syndrome are provided.